Streetbeat News

Analyst Ratings

ZVRA

Maxim Group analyst Jason McCarthy maintains a Buy rating on Zevra Therapeutics and raises the price target from $18 to $25.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 1:04 pm

PBH

Jefferies analyst Stephanie Wissink has assumed coverage of Prestige Consumer (NYSE:PBH) with a Hold rating and increased the price target to $76.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 1:02 pm

MESO

Maxim Group has upgraded Mesoblast (NASDAQ:MESO) from Hold to Buy, setting a price target of $12. This upgrade is based on analyst Jason McCarthy's assessment.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 1:01 pm

RMD

ResMed (NYSE:RMD) has received varied analyst ratings over the past three months, with a recent average price target of $227.57, up 3.68% from the previous target. Analysts' ratings range from 'Outperform' to 'Underperform', reflecting diverse expectations for ResMed's market performance. The company, a leader in respiratory care devices, has shown strong financial health with a 9.01% revenue growth rate and a net margin of 23.89%.

Portfolio Pulse from Benzinga Insights

September 24, 2024 | 1:01 pm

PG

Procter & Gamble (NYSE:PG) received mixed analyst ratings, with a majority being somewhat bullish. Analysts set an average 12-month price target of $177.5, indicating a 3.04% increase from the previous target. Despite a slight revenue decline, PG maintains strong net margins and effective asset utilization.

Portfolio Pulse from Benzinga Insights

September 24, 2024 | 1:01 pm

NEO

NeoGenomics (NASDAQ:NEO) has received recent analyst ratings, with 3 analysts being bullish and 1 somewhat bullish. The average 12-month price target is $18.5. Despite revenue growth, NeoGenomics faces challenges with profitability and returns, as indicated by its net margin, ROE, and ROA being below industry averages.

Portfolio Pulse from Benzinga Insights

September 24, 2024 | 1:00 pm

PCOR

Procore Technologies (NYSE:PCOR) has received diverse analyst ratings over the past three months, with a mix of bullish and neutral sentiments. The average 12-month price target has decreased by 14.63% to $70.69. Analysts have adjusted their ratings and price targets, reflecting changing market conditions and company performance. Despite a positive revenue growth rate of 24.42%, Procore faces challenges with profitability, ROE, and ROA, though it maintains a balanced debt approach.

Portfolio Pulse from Benzinga Insights

September 24, 2024 | 1:00 pm

DAY

Dayforce (NYSE:DAY) has received mixed analyst ratings over the past three months, with a majority being bullish or somewhat bullish. The average 12-month price target has slightly increased to $69.0. Analysts have adjusted their ratings and price targets, reflecting their response to recent developments. Dayforce has shown strong revenue growth but faces challenges in profitability and asset utilization.

Portfolio Pulse from Benzinga Insights

September 24, 2024 | 1:00 pm

COMP

Compass (NYSE:COMP) has received varied analyst ratings over the past quarter, with a mix of bullish and somewhat bullish sentiments. Analysts have raised their price targets, indicating a positive outlook. The company's financial performance shows strong revenue growth and efficient cost management, but it faces challenges in debt management.

Portfolio Pulse from Benzinga Insights

September 24, 2024 | 1:00 pm

FBLG

Maxim Group has initiated coverage on FibroBiologics with a Buy rating and set a price target of $12.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 12:59 pm